Pliant Therapeutics (PLRX) Competitors $1.51 +0.04 (+2.72%) Closing price 04:00 PM EasternExtended Trading$1.43 -0.08 (-5.30%) As of 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PLRX vs. MREO, RVNC, RAPP, SLDB, HRTX, ALLO, ARCT, ATXS, GLUE, and CYRXShould you be buying Pliant Therapeutics stock or one of its competitors? The main competitors of Pliant Therapeutics include Mereo BioPharma Group (MREO), Revance Therapeutics (RVNC), Rapport Therapeutics (RAPP), Solid Biosciences (SLDB), Heron Therapeutics (HRTX), Allogene Therapeutics (ALLO), Arcturus Therapeutics (ARCT), Astria Therapeutics (ATXS), Monte Rosa Therapeutics (GLUE), and Cryoport (CYRX). These companies are all part of the "pharmaceutical products" industry. Pliant Therapeutics vs. Mereo BioPharma Group Revance Therapeutics Rapport Therapeutics Solid Biosciences Heron Therapeutics Allogene Therapeutics Arcturus Therapeutics Astria Therapeutics Monte Rosa Therapeutics Cryoport Pliant Therapeutics (NASDAQ:PLRX) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, community ranking, institutional ownership and earnings. Does the media prefer PLRX or MREO? In the previous week, Mereo BioPharma Group had 7 more articles in the media than Pliant Therapeutics. MarketBeat recorded 12 mentions for Mereo BioPharma Group and 5 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 0.30 beat Mereo BioPharma Group's score of 0.11 indicating that Pliant Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pliant Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mereo BioPharma Group 0 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate PLRX or MREO? Pliant Therapeutics presently has a consensus target price of $13.31, indicating a potential upside of 781.62%. Mereo BioPharma Group has a consensus target price of $7.71, indicating a potential upside of 220.09%. Given Pliant Therapeutics' higher possible upside, equities research analysts clearly believe Pliant Therapeutics is more favorable than Mereo BioPharma Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pliant Therapeutics 0 Sell rating(s) 12 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Mereo BioPharma Group 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25 Which has more volatility & risk, PLRX or MREO? Pliant Therapeutics has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. Comparatively, Mereo BioPharma Group has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Is PLRX or MREO more profitable? Mereo BioPharma Group's return on equity of 0.00% beat Pliant Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Pliant TherapeuticsN/A -48.91% -41.09% Mereo BioPharma Group N/A N/A N/A Do insiders and institutionals hold more shares of PLRX or MREO? 97.3% of Pliant Therapeutics shares are owned by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are owned by institutional investors. 6.4% of Pliant Therapeutics shares are owned by insiders. Comparatively, 4.1% of Mereo BioPharma Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has better earnings and valuation, PLRX or MREO? Mereo BioPharma Group has lower revenue, but higher earnings than Pliant Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPliant Therapeutics$1.58M58.52-$161.34M-$3.47-0.44Mereo BioPharma Group$1M373.90-$29.47MN/AN/A Does the MarketBeat Community prefer PLRX or MREO? Pliant Therapeutics received 24 more outperform votes than Mereo BioPharma Group when rated by MarketBeat users. However, 80.00% of users gave Mereo BioPharma Group an outperform vote while only 63.87% of users gave Pliant Therapeutics an outperform vote. CompanyUnderperformOutperformPliant TherapeuticsOutperform Votes7663.87% Underperform Votes4336.13% Mereo BioPharma GroupOutperform Votes5280.00% Underperform Votes1320.00% SummaryMereo BioPharma Group beats Pliant Therapeutics on 9 of the 16 factors compared between the two stocks. Remove Ads Get Pliant Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLRX vs. The Competition Export to ExcelMetricPliant TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$92.47M$6.91B$5.64B$8.06BDividend YieldN/A2.73%4.56%4.02%P/E Ratio-0.457.2023.1319.03Price / Sales58.52226.00383.8993.17Price / CashN/A65.6738.1634.64Price / Book0.196.476.944.33Net Income-$161.34M$141.90M$3.20B$247.06M7 Day Performance-4.43%-3.05%-2.32%-0.53%1 Month Performance-53.68%-4.63%3.07%-3.74%1 Year Performance-89.62%-8.61%11.16%1.72% Pliant Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLRXPliant Therapeutics4.3322 of 5 stars$1.51+2.7%$13.31+781.6%-89.6%$92.47M$1.58M-0.4590Short Interest ↑MREOMereo BioPharma Group2.4294 of 5 stars$2.49+4.6%$7.83+214.6%-19.7%$386.31M$1M0.0040Earnings ReportAnalyst ForecastNews CoveragePositive NewsRVNCRevance Therapeutics2.0263 of 5 stars$3.65flat$8.39+129.7%N/A$381.02M$234.04M-1.89500Analyst ForecastRAPPRapport Therapeutics1.7513 of 5 stars$10.22+5.1%$35.00+242.5%N/A$372.99MN/A-0.74N/AShort Interest ↑SLDBSolid Biosciences3.575 of 5 stars$4.78+3.9%$15.67+227.8%-68.6%$370.42M$8.09M-1.57100HRTXHeron Therapeutics3.8886 of 5 stars$2.43+2.1%$5.67+133.2%-16.4%$370.16M$144.29M-13.50300Positive NewsALLOAllogene Therapeutics3.0594 of 5 stars$1.68+3.7%$9.29+452.9%-62.7%$365.01M$22,000.00-1.08310Gap UpARCTArcturus Therapeutics2.7633 of 5 stars$13.27+3.0%$59.20+346.1%-62.8%$359.88M$138.39M-5.98180ATXSAstria Therapeutics1.7913 of 5 stars$6.37-0.6%$26.67+318.6%-54.8%$359.49MN/A-3.0530GLUEMonte Rosa Therapeutics2.9889 of 5 stars$5.83+0.5%$15.50+165.9%-16.7%$358.18M$14.98M-3.1990Earnings ReportShort Interest ↓Analyst RevisionCYRXCryoport2.5841 of 5 stars$7.10+24.8%$11.67+64.3%-64.1%$354.36M$228.39M-2.101,020Upcoming EarningsPositive NewsHigh Trading Volume Remove Ads Related Companies and Tools Related Companies MREO Alternatives RVNC Alternatives RAPP Alternatives SLDB Alternatives HRTX Alternatives ALLO Alternatives ARCT Alternatives ATXS Alternatives GLUE Alternatives CYRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PLRX) was last updated on 3/27/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pliant Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pliant Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
